Broekmans A W
Haemostasis. 1985;15(4):233-40. doi: 10.1159/000215154.
Hereditary protein C deficiency, which is inherited as an autosomal-dominant trait, predisposes to venous thrombotic disease. Heterozygotes are at risk for superficial thrombophlebitis, deep venous thrombosis and/or pulmonary embolism, which may occur without apparent cause at a young age. Other manifestations are cerebral venous thrombosis and mesenteric vein thrombosis. In severe, often homozygous, protein C deficiency, a purpura fulminans syndrome may occur shortly after birth, resulting in death due to extensive thrombosis, if it is not adequately treated. The thrombotic manifestations in heterozygotes are effectively prevented by coumarin therapy. However, in the initial phase of oral anticoagulant therapy, the patients have an increased risk for the development of coumarin-induced haemorrhagic skin necrosis. The purpura fulminans syndrome can be treated with either replacement therapy or with coumarin therapy. Heparin appears to be ineffective in the prevention of both the purpura fulminans syndrome and the coumarin-induced skin necrosis.
遗传性蛋白C缺乏症以常染色体显性性状遗传,易引发静脉血栓形成疾病。杂合子有患浅表血栓性静脉炎、深静脉血栓形成和/或肺栓塞的风险,这些病症可能在年轻时无明显诱因出现。其他表现包括脑静脉血栓形成和肠系膜静脉血栓形成。在严重的、通常为纯合子的蛋白C缺乏症中,出生后不久可能会出现暴发性紫癜综合征,如不进行充分治疗,会因广泛血栓形成而导致死亡。杂合子的血栓形成表现可通过香豆素治疗有效预防。然而,在口服抗凝治疗的初始阶段,患者发生香豆素诱导的出血性皮肤坏死的风险增加。暴发性紫癜综合征可用替代疗法或香豆素疗法治疗。肝素似乎对预防暴发性紫癜综合征和香豆素诱导的皮肤坏死均无效。